Advertisement

Topics

PubMed Journals Articles About "CAFC Affirms Apotex Biosimilars Infringe Amgen Patent" - Page: 3 RSS

23:49 EDT 21st September 2018 | BioPortfolio

CAFC Affirms Apotex Biosimilars Infringe Amgen Patent PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest CAFC Affirms Apotex Biosimilars Infringe Amgen Patent articles that have been published worldwide.

More Information about "CAFC Affirms Apotex Biosimilars Infringe Amgen Patent" on BioPortfolio

We have published hundreds of CAFC Affirms Apotex Biosimilars Infringe Amgen Patent news stories on BioPortfolio along with dozens of CAFC Affirms Apotex Biosimilars Infringe Amgen Patent Clinical Trials and PubMed Articles about CAFC Affirms Apotex Biosimilars Infringe Amgen Patent for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CAFC Affirms Apotex Biosimilars Infringe Amgen Patent Companies in our database. You can also find out about relevant CAFC Affirms Apotex Biosimilars Infringe Amgen Patent Drugs and Medications on this site too.

Showing "CAFC affirms Apotex biosimilars infringe Amgen patent" PubMed Articles 51–75 of 241

Paradoxical brain embolism shadowing massive pulmonary embolism.

Patent foramen ovale is frequently observed in the general population. In case of massive pulmonary embolism, the sudden increase in the right heart cavity's pressure may cause a right-to-left shunting across this foramen, which could be associated with conflicting outcomes. Herein, we report a case of reversible cardiac arrest preceded by seizures, and followed by hemodynamic stability without any vasopressor. A brain CT-scan showed a limited ischemic stroke. Initial echocardiographic assessment revealed a...


Use of Amplatzer vascular plugs and Amplatzer duct occluder II additional sizes for occlusion of patent ductus arteriosus: A multi-institutional study.

Variable patent ductus arteriosus (PDA) morphology and the need to close PDAs in small size patients has led physicians to use Amplatzer Vascular Plugs (AVP) and recently available Amplatzer Duct Occluder II - Additional Sizes (ADO II AS). The purpose of this study was to analyze the safety, efficacy, and complication rates of the ADO II AS and AVPs, specifically AVP II.

Partnership for productive development of biosimilar products: perspectives of access to biological products in the Brazilian market.

The manufacturing process for biological products is complex, expensive and critical to the final product, with an impact on their efficacy and safety. They have been increasingly used to treat several diseases, and account for approximately 50% of the yearly budget for the Brazilian public health system. As the patents of biological products expire, several biosimilars are developed. However, there are concerns regarding their efficacy and safety; therefore, the regulatory agencies establish rules to appro...


Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials.

The efficacy of patent foramen ovale (PFO) closure for cryptogenic stroke has been controversial. We undertook a meta-analysis of randomized controlled trials (RCTs) comparing device closure with medical therapy to prevent recurrent stroke for patients with PFO.

Forecasting new product diffusion using both patent citation and web search traffic.

Accurate demand forecasting for new technology products is a key factor in the success of a business. We propose a way to forecasting a new product's diffusion through technology diffusion and interest diffusion. Technology diffusion and interest diffusion are measured by the volume of patent citations and web search traffic, respectively. We apply the proposed method to forecast the sales of hybrid cars and industrial robots in the US market. The results show that that technology diffusion, as represented ...

EPO revokes Broad's CRISPR patent.

University of California's first CRISPR patent win.

Patent foramen ovale closure or medical therapy for cryptogenic ischemic stroke: an updated meta-analysis of randomized controlled trials.

Previous randomized controlled trials (RCT) failed to demonstrate benefits of patent foramen ovale (PFO) closure (PFO-C) over medical therapy (MT) for secondary prevention of cryptogenic ischemic stroke. Three recently published RCTs, however, turned out positive for PFO-C and warrant an updated meta-analysis.

Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.

The evil of the patent foramen ovale: we are seeing but the tip of the iceberg.

Gender differences in obtaining and maintaining patent rights.

AI-generated in silico data in patent applications.

Inadvertent Extracorporeal Membrane Oxygenation Cannulation across a Patent Foramen Ovale.

Caught in the Act: Thrombus Wedged in a Patent Foramen Ovale.

What is the optimal surgical strategy for Stanford Type A acute aortic dissection in patients with a patent false lumen at the descending aorta?

Aggressive total arch replacement (TAR) to obtain thrombosis of the distal false lumen (FL) in patients with Stanford Type A acute aortic dissection, particularly with a patent FL at the descending aorta, is discussed. The aim of this study was to examine the efficacy of our strategy.

Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events.

About one-third of ischemic stroke are cryptogenic. Paradoxical embolism through patent foramen ovale (PFO) has been identified as a possible cause of cryptogenic stroke. Therefore, PFO closure has been considered for secondary prevention of cryptogenic stroke. However, randomized clinical trials (RCTs) comparing PFO closure versus medical therapy led to conflicting results. Our objectives were to examine if PFO closure is superior to medical therapy alone for secondary prevention of cryptogenic stroke and ...

Endovascular treatment of an aortic aneurysm and patent ductus arteriosus.

Immune checkpoint inhibitors myocarditis: not all cases are clinically patent.

Analyzing the protection scope limit for biosequence patent claims in China.

A database linking Chinese patents to China's census firms.

To meet researchers' increasing interest in the fast growing innovation activities taking place in China, we match patents filed with China's State Intellectual Property Office to firms covered in China's Census. China has experienced a strong growth in patent filings over the past two decades, and has since 2011 become the world's top patent filing country. China's Census database covers about one million unique manufacturing firms from 1998-2009, representing the broad Chinese economy. We design data pars...

Patent mining and landscaping of emerging recombinant factor VIII through network analysis.

Patent foramen ovale increases stroke risk in older people.

The Norwood Procedure with Valvular Pulmonary Stenosis.

A combination of hypoplasia of the left side of the heart, a hypoplastic aortic arch, a large patent ductus arteriosus, and valvular pulmonary stenosis is very rare. The severity of the valvular pulmonary stenosis in this setting is difficult to judge preoperatively. Here, we describe a newborn with borderline hypoplasia of the left side of the heart, a hypoplastic aortic arch, a large patent ductus arteriosus, and valvular pulmonary stenosis, who underwent the Norwood procedure successfully. The purpose of...

Thrombus in a Hypercoagulable Patient Following Patent Foramen Ovale Closure With the Gore Septal Occluder.

Closure of the patent foramen ovale stepping out of the Cinderella role.


Advertisement
Quick Search
Advertisement
Advertisement